MYmAb Biologics Recognised as VIP at Healthcare+ Expo Taiwan, Strengthening Its Global Healthcare Presence MYmAb Biologics is honoured to be invited as a VIP guest at the Healthcare+ Expo Taiwan, held at the Taipei Nangang Exhibition Center. The invitation reflects…
MYmAb Biologics Expands Global Reach Through Strategic Distributor Partnerships, Advancing Equity in Cancer Research Strengthening its international footprint, MYmAb Biologics has entered strategic collaborations with two well-established global distributors: ABreal Biotech and 2BScientific. These partnerships mark a significant milestone in…
Dr Chua Jia Xin: Advancing Therapeutic Antibodies for Malaysia and Beyond Dr Chua Jia Xin’s recognition as the National Young Scientist Award 2025 recipient in the Medical category highlights the rising strength of Malaysia’s biotechnology talent. As the founder of…
Tissue Microarray for Prostate Cancer: Accelerating Biomarker Discovery and Precision Oncology In the evolving field of oncology research, precision, scalability, and reproducibility are key drivers of progress. Prostate cancer, one of the most prevalent malignancies among men worldwide, presents significant…
Tissue Microarray (TMA): The Future of Tissue-Based Research and Diagnostics In modern biomedical research, efficiency and precision define progress. One of the most impactful technologies driving that progress is the tissue microarray (TMA) — a platform that allows researchers to…
MYmAb Biologics Invited as Host Company for BeST Programme 2.0 We are proud to announce that MYmAb Biologics has been invited to serve as a host company for the BeST Programme 2.0, an initiative by Bioeconomy Corporation to nurture skilled…
MYmAb Biologics Featured on CBS News: Bringing Equity to Global Cancer Innovation We are proud to share that MYmAb Biologics and our Founder & Director, Dr. Chua Jia Xin, were recently featured on CBS News in a special story highlighting…
How Tissue Microarrays Facilitate Tumour Microenvironment (TME) Research What is the Tumour Microenvironment (TME)? The tumour microenvironment (TME) is a complex ecosystem surrounding a tumour that supports cancer cell growth and progression. It is composed of tumour cells, stromal cells,…
MYmAb Biologics Recognized as a BioNexus Status Company March 2025 – We are thrilled to announce that MYmAb Biologics has been awarded BioNexus Status by the Bioeconomy Corporation. This prestigious recognition marks a significant milestone in our mission to drive…
Tissue Microarrays (TMAs): Applications in Tumour Biology Tissue Microarrays (TMAs) have transformed cancer research, offering an innovative platform to investigate molecular alterations, tumour progression, and clinical outcomes. Suitable for virtually all tissue types, TMAs provide unmatched efficiency and scalability, making…